Associated tags: BK virus, Viral, Cytomegalovirus, Infection, Patient, BK, Pelvic floor dysfunction, Cancer, Vaccine, Pharmaceutical industry, BKV, MTX, Pharmaceutical, Biotechnology, Health, Clinical trial, Clinical Trials, Survival, Therapy, Pharmacokinetics, Viral load, Polyomaviridae, Immunosuppression, Longevity, Infectious Diseases, Kidney transplantation
Locations: JAPAN, NORTH AMERICA, SWEDEN, SCHLIEREN, ZURICH, CH, SWITZERLAND, NETHERLANDS, EUROPE
FDA,
Phase,
Cancer,
Venture round,
BK,
Kidney,
Risk,
MTX,
BK virus,
Viremia,
Memo,
Disease,
Patient,
Kidney transplantation,
BKV,
CHF,
Infection,
Therapy,
Viral,
Pharmaceutical industry Schlieren / Zurich, Switzerland, 7 May, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company developing a best-in-class BKV-neutralizing antibody for BKV infection in kidney transplantation, today announces that it has successfully raised CHF 20 million as part of an extension of its Series C financing, bringing the total amount raised in the funding round to CHF 45 million.
Key Points:
- Schlieren / Zurich, Switzerland, 7 May, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company developing a best-in-class BKV-neutralizing antibody for BKV infection in kidney transplantation, today announces that it has successfully raised CHF 20 million as part of an extension of its Series C financing, bringing the total amount raised in the funding round to CHF 45 million.
- Erik van den Berg, CEO of Memo Therapeutics, commented: “This financing provides further external endorsement of the potential of our highly potent anti-BK virus mAb and our clinical strategy to bring it to patients as quickly as possible.
- Thomas Harth, Principal at Ysios Capital stated: “We believe Memo Therapeutics has developed a very powerful antibody that can address the growing concern of BKV infections in kidney transplant recipients.
- Alongside AntiBKV, Memo Therapeutics is developing a panel of pre-clinical assets in cancer and viral infections.
FDA,
Phase,
Cancer,
Venture round,
BK,
Kidney,
Risk,
MTX,
BK virus,
Viremia,
Memo,
Disease,
Patient,
Kidney transplantation,
BKV,
CHF,
Infection,
Therapy,
Viral,
Pharmaceutical industry Schlieren / Zurich, Switzerland, 7 May, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company developing a best-in-class BKV-neutralizing antibody for BKV infection in kidney transplantation, today announces that it has successfully raised CHF 20 million as part of an extension of its Series C financing, bringing the total amount raised in the funding round to CHF 45 million.
Key Points:
- Schlieren / Zurich, Switzerland, 7 May, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company developing a best-in-class BKV-neutralizing antibody for BKV infection in kidney transplantation, today announces that it has successfully raised CHF 20 million as part of an extension of its Series C financing, bringing the total amount raised in the funding round to CHF 45 million.
- Erik van den Berg, CEO of Memo Therapeutics, commented: “This financing provides further external endorsement of the potential of our highly potent anti-BK virus mAb and our clinical strategy to bring it to patients as quickly as possible.
- Thomas Harth, Principal at Ysios Capital stated: “We believe Memo Therapeutics has developed a very powerful antibody that can address the growing concern of BKV infections in kidney transplant recipients.
- Alongside AntiBKV, Memo Therapeutics is developing a panel of pre-clinical assets in cancer and viral infections.
Leiden University,
Bachelor of Science,
Supply chain management,
CMC,
Chemistry,
Wageningen University & Research,
PPD,
Maartje (name),
Master of Science,
MTX,
AbbVie,
Barton College,
Doctor of Philosophy,
Viral,
Nursing,
Pharmaceutical industry Ms. Clemmer is an accomplished global clinical research leader with over 20 years of experience directing international clinical operations.
Key Points:
- Ms. Clemmer is an accomplished global clinical research leader with over 20 years of experience directing international clinical operations.
- Ms. Clemmer previously held senior leadership positions at the Contract Research Organizations PRA Health Sciences and PPD.
- She joins MTx from AM-Pharma, where she was responsible for all drug substance activities including Phase III clinical manufacturing.
- Eric van den Berg, CEO of MTx, commented: “It is a pleasure to welcome Kristie and Maartje to MTx.
Retrieved on:
Thursday, November 16, 2023
Oncology,
Health,
Clinical Trials,
Research,
Science,
Pharmaceutical,
Biotechnology,
Pfizer,
Integra,
Chemistry,
MTX,
Kyowa Kirin,
University College Utrecht,
Patient,
Multimedia,
Isoti,
FDA,
Alliance Manchester Business School,
IPO,
MBA,
University,
Partnership,
Integra LifeSciences,
Fast Track,
Organon,
Management Memo Therapeutics AG (“MTx”), a late-stage biotech company developing best-in-class therapeutic antibodies, announced today the appointment of Erik van den Berg as Chief Executive Officer (CEO).
Key Points:
- Memo Therapeutics AG (“MTx”), a late-stage biotech company developing best-in-class therapeutic antibodies, announced today the appointment of Erik van den Berg as Chief Executive Officer (CEO).
- View the full release here: https://www.businesswire.com/news/home/20231115733368/en/
Erik van den Berg, CEO of Memo Therapeutics AG (Photo: Business Wire)
Mr. van den Berg joins MTx with over 25 years’ industry experience and proven track record in leading and growing companies.
- Previously, Mr. van den Berg also held business development roles at Organon and IsoTis (sold to Integra Lifesciences).
- Mr. van den Berg holds a master’s degree in chemistry from the University of Utrecht and an MBA from Manchester Business School.
Retrieved on:
Thursday, November 2, 2023
Oncology,
Health,
Other Health,
Clinical Trials,
Pharmaceutical,
Biotechnology,
Survival,
CMC,
Infection,
Phase,
BK,
BKV,
Patient,
Pharmaceutical industry,
Vaccine,
MTX Memo Therapeutics AG (“MTx”), a late-stage biotech company developing best-in-class therapeutic antibodies, announced today the closing of a CHF25 million Series C financing led by Pureos Bioventures.
Key Points:
- Memo Therapeutics AG (“MTx”), a late-stage biotech company developing best-in-class therapeutic antibodies, announced today the closing of a CHF25 million Series C financing led by Pureos Bioventures.
- Phase II clinical development of its best- and first-in-class antibody, AntiBKV, intended to neutralize BK polyomavirus (“BKV”) infection in kidney transplant recipients.
- BKV infection poses a significant threat following the transplantation procedure, with serious adverse effects on graft function and ultimately patient survival.
- “With these new funds, we are in an optimal position to complete a multi-center Phase II study with AntiBKV, a treatment option that could dramatically improve the lives of renal transplant patients.
Biotechnology,
Infectious Diseases,
Health,
Pharmaceutical,
Clinical Trials,
Infection,
Viremia,
MTX,
Survival,
Clinical trial,
Polyomaviridae,
Fast Track,
Patient,
TFS,
Risk,
Blood,
Kidney transplantation,
Viral load,
BKV,
Longevity,
Phase,
Immunosuppression,
Regulation of food and dietary supplements by the U.S. Food and Drug Administration,
BK,
Food,
Pharmaceutical industry Phase II/III trial of AntiBKV, MTx’s antibody therapeutic that targets BK polyomavirus (“BKV”) infection in renal transplant patients.
Key Points:
- Phase II/III trial of AntiBKV, MTx’s antibody therapeutic that targets BK polyomavirus (“BKV”) infection in renal transplant patients.
- “The start of this U.S. pivotal Phase II/III clinical trial with AntiBKV is a significant milestone for us.
- We believe that AntiBKV, with its 100x more potent neutralization capacity than benchmark antibodies, has great potential to help renal transplant patients.
- The Phase II part is a randomized, placebo-controlled trial designed to evaluate the therapeutic efficacy of AntiBKV in 60 renal transplant patients with BK viremia.
FDA,
Health,
Infectious Diseases,
Clinical Trials,
Pharmaceutical,
Biotechnology,
Infection,
Therapy,
Survival,
Polyomaviridae,
Fast Track,
Patient,
Risk,
Kidney transplantation,
BKV,
Longevity,
Immunosuppression,
Regulation of food and dietary supplements by the U.S. Food and Drug Administration,
BK,
BLA,
Food,
Pharmaceutical industry Memo Therapeutics AG (“MTx”), a biotech company developing best-in-class therapeutic antibodies, announced today that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation to AntiBKV, MTx’s lead antibody therapeutic that targets BK polyomavirus (“BKV”) infection commonly seen in renal transplant patients.
Key Points:
- Memo Therapeutics AG (“MTx”), a biotech company developing best-in-class therapeutic antibodies, announced today that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation to AntiBKV, MTx’s lead antibody therapeutic that targets BK polyomavirus (“BKV”) infection commonly seen in renal transplant patients.
- “Receiving Fast Track designation from the FDA is a significant achievement for Memo, validating the potential of AntiBKV and expediting its development.
- We believe AntiBKV could be a first- and best-in-class treatment option for kidney transplant patients suffering from BKV infection,” said Dr. Karsten Fischer, Chief Executive Officer of Memo Therapeutics AG.
- Due to the immunosuppressive drug regimen transplant patients receive, reactivation of BKV is triggered in 40 to 50% of kidney transplant recipients.
Retrieved on:
Tuesday, January 24, 2023
Biotechnology,
Infectious Diseases,
Health,
Pharmaceutical,
Clinical Trials,
BK,
Trial of the century,
MTX,
Safety,
Patient,
Clinical trial,
Risk,
USD,
BKV,
Kidney transplantation,
Survival,
Infection,
Volunteering,
Polyomaviridae,
Immunosuppression,
Pharmacokinetics,
Longevity,
Pharmaceutical industry Memo Therapeutics AG (“MTx”), an innovator in the field of antibody discovery and development, announced today positive safety and tolerability data from a Phase I clinical trial with AntiBKV, an antibody targeting BK polyomavirus (“BKV”) infection in renal transplant patients, meeting its primary endpoint.
Key Points:
- Memo Therapeutics AG (“MTx”), an innovator in the field of antibody discovery and development, announced today positive safety and tolerability data from a Phase I clinical trial with AntiBKV, an antibody targeting BK polyomavirus (“BKV”) infection in renal transplant patients, meeting its primary endpoint.
- “AntiBKV has the potential to be a best- and first-in-class antibody for the treatment of BKV infection in kidney transplant recipients.
- BKV infection poses a significant threat in kidney transplantation, with serious adverse effects on graft function and ultimately patient survival.
- Up to 10% of these cases progress to BKV associated nephropathy, which poses a serious threat to the transplant.
Retrieved on:
Wednesday, January 25, 2023
VPM,
MTX,
Infection,
IND,
BK,
Pharmacokinetics,
Therapy,
Drug development,
Trial of the century,
Patient,
Volunteering,
Drug discovery,
Viral load,
Clinical trial,
Knowledge,
BKV,
Fine chemical,
Pharmaceutical industry The project included a Phase I clinical trial with AntiBKV, an antibody targeting BK polyomavirus (BKV) infection in renal transplant patients.
Key Points:
- The project included a Phase I clinical trial with AntiBKV, an antibody targeting BK polyomavirus (BKV) infection in renal transplant patients.
- VPM oversaw the clinical trial and performed translational project management, whereas the Australian cooperation partner and contract research organization (CRO) Accelagen managed the trial, yielding positive results, with all endpoints met.
- In this phase I, single-blind, partially randomized, placebo-controlled clinical trial, 40 healthy adult volunteers were administered single and multiple ascending intravenous doses of AntiBKV (ClinicalTrials.gov: NCT05358106).
- The broad expertise and commitment of VPM made the trial run smoothly, within budget and on time.
Retrieved on:
Thursday, February 2, 2023
IND,
VPM,
Infection,
Therapy,
Viral load,
Trial of the century,
Pharmacokinetics,
Knowledge,
Drug development,
BK,
BKV,
Drug discovery,
Patient,
Clinical trial,
Volunteering,
MTX,
Fine chemical,
Pharmaceutical industry The project included a Phase I clinical trial with AntiBKV, an antibody targeting BK polyomavirus (BKV) infection in renal transplant patients.
Key Points:
- The project included a Phase I clinical trial with AntiBKV, an antibody targeting BK polyomavirus (BKV) infection in renal transplant patients.
- VPM oversaw the clinical trial and performed translational project management, whereas the Australian cooperation partner and contract research organization (CRO) Accelagen managed the trial, yielding positive results, with all endpoints met.
- In this phase I, single-blind, partially randomized, placebo-controlled clinical trial, 40 healthy adult volunteers were administered single and multiple ascending intravenous doses of AntiBKV (ClinicalTrials.gov: NCT05358106).
- The broad expertise and commitment of VPM made the trial run smoothly, within budget and on time.
